Corbus Pharmaceuticals Holdings, Inc. (CRBP) financial statements (2020 and earlier)

Company profile

Business Address 100 RIVER RIDGE DRIVE
NORWOOD, MA 02062
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments32557390425665
Cash and cash equivalents32557390425665
Prepaid expense    233
Other undisclosed current assets6323   
Total current assets:38587593445868
Noncurrent Assets
Operating lease, right-of-use asset6666
Property, plant and equipment5533333
Other noncurrent assets0000000
Total noncurrent assets:111199333
TOTAL ASSETS:496884101476170
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3430272516149
Accounts payable11679663
Accrued liabilities222419161076
Deferred revenue  227
Debt10010 0
Deferred rent credit    0  
Contract with customer, liability1  
Other undisclosed current liabilities     34
Total current liabilities:35312952181713
Noncurrent Liabilities
Long-term debt and lease obligation8877   
Operating lease, liability8877
Liabilities, other than long-term debt    111
Deferred rent credit    111
Total noncurrent liabilities:8877111
Total liabilities:43383759191815
Stockholders' equity
Stockholders' equity attributable to parent6304742284355
Common stock0000000
Additional paid in capital199196193190149147145
Accumulated deficit(193)(166)(145)(148)(121)(104)(89)
Total stockholders' equity:6304742284355
TOTAL LIABILITIES AND EQUITY:496884101476170

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:33292211
Operating expenses(30)(28)(27)(28)(20)(16)(13)
Operating income (loss):(27)(25)2(27)(18)(15)(12)
Nonoperating income1400000
Foreign currency transaction gain (loss), before tax (0)(0)(0)000
Other nonoperating income 4     
Interest and debt expense (0)(0)(0) (0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes0   0  
Net income (loss):(27)(21)2(26)(17)(15)(12)
Other undisclosed net income (loss) attributable to parent(0)000(0)00
Net income (loss) available to common stockholders, diluted:(27)(21)2(26)(17)(15)(12)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(27)(21)2(26)(17)(15)(12)
Comprehensive income (loss), net of tax, attributable to parent:(27)(21)2(26)(17)(15)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: